Biotech Voic­es: Coro­n­avirus will change biotech re­search with re­mote col­lab­o­ra­tions

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to senior editors Kyle Blankenship and Amber Tong.

When a field that de­pends on sci­en­tif­ic bench­work sud­den­ly moves on­line, what hap­pens to col­lab­o­ra­tions and the in­no­va­tion sup­ply chain? We are see­ing the an­swer to this ques­tion play out in re­al time dur­ing the Covid-19 cri­sis. Across the Unit­ed States and abroad, mea­sures to safe­guard against this se­ri­ous dis­ease have cre­at­ed an un­planned, mas­sive test for re­mote work in biotech­nol­o­gy.

Sci­en­tif­ic com­pa­nies face a unique chal­lenge dur­ing the shut­down: con­tin­u­ing their re­search. Lab-based work re­quires in-per­son, hu­man at­ten­tion, as many ex­per­i­ments are com­plex and re­quire spe­cial­ized ex­per­tise. These projects are of­ten achieved through re­search col­lab­o­ra­tions be­tween or­ga­ni­za­tions, re­quir­ing meet­ings to share da­ta, shared work en­vi­ron­ments, and deep dis­cus­sions. And their re­sults are price­less — these col­lab­o­ra­tions have the po­ten­tial to gen­er­ate ther­a­pies that save or im­prove mil­lions of lives in the fu­ture. This is why biotech­nol­o­gy com­pa­nies have been deemed an es­sen­tial in­dus­try and con­tin­ue to op­er­ate in some form dur­ing the shut­down.

Of course, the in­dus­try — like many oth­ers — has rapid­ly adapt­ed. With bans on trav­el and re­stric­tions on in-per­son work and meet­ings, many of the sci­en­tif­ic col­lab­o­ra­tions that gen­er­ate new ther­a­pies are now 100% vir­tu­al. This shift presents unique chal­lenges as well as op­por­tu­ni­ties.

It’s im­pos­si­ble to ful­ly re­place in-per­son work with Zoom video and con­fer­ence calls. Face-to-face com­mu­ni­ca­tion will con­tin­ue to be im­por­tant, even af­ter the acute coro­n­avirus pan­dem­ic eas­es and some sem­blance of nor­mal op­er­a­tions recom­mences. That said, it’s cru­cial that com­pa­nies con­tin­ue to pro­tect em­ploy­ees and pri­or­i­tize their com­fort and safe­ty. The need for safe, low-risk busi­ness en­vi­ron­ments will con­tin­ue to be nec­es­sary, and we will all need to ad­just and adapt to col­lab­o­ra­tions with less — and some­times no — in-per­son in­ter­ac­tions.

As the need for re­mote work con­tin­ues, it will dri­ve big changes in how biotech com­pa­nies ap­proach re­search col­lab­o­ra­tions and part­ner­ing ac­tiv­i­ty.

Sci­ence will be “de-den­si­fied”

Across in­dus­tries, busi­ness­es are look­ing for ways to “de-den­si­fy” work en­vi­ron­ments to pro­tect em­ploy­ees. Biotech is no dif­fer­ent. Un­til we have re­li­able and wide­ly-avail­able tests for Covid-19 — both an­ti­body tests and serol­o­gy tests — to sup­port safer work­spaces, labs will need to adapt. Al­ready, biotech com­pa­nies are cre­at­ing new work struc­tures to en­sure that em­ploy­ee health is pro­tect­ed and sci­en­tists spend the least amount of time to­geth­er in the lab.

New struc­tures with more re­mote work mean that sci­en­tif­ic teams will be­come greater ex­perts at plan­ning and com­mu­ni­ca­tion. At my com­pa­ny, for ex­am­ple, we have im­ple­ment­ed a shift-based ap­proach, send­ing teams in­to the lab for two-week sprints, fol­lowed by two weeks of re­mote of­fice work. With this sys­tem, we al­ways have a core team in the lab for es­tab­lished process­es such as tis­sue cul­ture, bio­chem­istry, in-vi­vo, phar­ma­col­o­gy, and more. These shifts are ac­com­pa­nied by tem­per­a­ture checks and oth­er mea­sures to en­sure our team feels and is safe, and that our labs are at low­est pos­si­ble risk for spread­ing Covid-19. Feed­back from our teams re­flects chal­lenges — we can­not work at the same den­si­ty or ef­fi­cien­cy as be­fore — but we al­so see that teams have learned to work more in­ti­mate­ly to com­pen­sate. Fur­ther­more, our most in­no­v­a­tive sci­en­tists are ac­cel­er­at­ing our ef­forts in bioin­for­mat­ics and the use of AI in bi­o­log­i­cal imag­ing and drug de­sign, all of which can be ac­com­plished re­mote­ly af­ter key da­ta have been gen­er­at­ed in the labs.

Re­search col­lab­o­ra­tions will be­come more glob­al

Biotech clus­ters like Boston, New York, and San Fran­cis­co have many ben­e­fits, one of which is den­si­ty of col­lab­o­ra­tors and part­ners, such as uni­ver­si­ties and Big Phar­ma play­ers. Big name com­pa­nies spend huge amounts of cap­i­tal on R&D col­lab­o­ra­tion, and many drugs are born from part­ner­ships based on phys­i­cal prox­im­i­ty.

Re­mote col­lab­o­ra­tion was al­ways tech­no­log­i­cal­ly pos­si­ble, and has been a key strat­e­gy for biotech for years. How­ev­er, hav­ing an in­no­va­tion chain dom­i­nat­ed by re­mote col­lab­o­ra­tion in the ear­ly dis­cov­ery space is an untest­ed con­cept. Now, we’re see­ing that glob­al col­lab­o­ra­tion is more vi­able than per­haps an­tic­i­pat­ed. With the right tools and process­es, sci­en­tif­ic teams can work well across bound­aries.

More glob­al col­lab­o­ra­tions au­to­mat­i­cal­ly lead to more di­ver­si­ty, which of­ten im­proves ideas and ap­proach­es. With dis­trib­uted col­lab­o­ra­tions, the qual­i­ty of re­search and find­ings will al­so grow. Bet­ter ther­a­peu­tics are a net pos­i­tive for the health­care in­dus­try and pa­tients.

Pri­or­i­ties will be­come more reg­i­ment­ed

Sci­ence is a cre­ative process, with room for wan­der­ing, imag­i­na­tive it­er­a­tion. Suc­cess­ful in­no­va­tion, how­ev­er, has al­ways re­quired dis­ci­plined con­cen­tra­tion. With re­duced lab ca­pac­i­ty due to de-den­si­fied work en­vi­ron­ments, com­pa­nies will now need to hone their fo­cus like nev­er be­fore.

For com­pa­nies with a sin­gle as­set, this will mean a laser-fo­cused ap­proach to re­search, with less room for tan­gen­tial work. For plat­form com­pa­nies — like my own — whose bi­o­log­i­cal in­sights al­low the tar­get­ing of mul­ti­ple dis­eases, teams will need to quick­ly de­cide which paths to pur­sue alone and which would fit bet­ter in col­lab­o­ra­tion. No mat­ter what, the “nice to dos” will fall away in fa­vor of the “need to dos.” Fast for­ward to the fu­ture, and this nec­es­sary triage may re­sult in a bumper crop of valu­able ther­a­peu­tics.

Best prac­tices for man­ag­ing a re­mote col­lab­o­ra­tion

Over my ca­reer, like many oth­ers, I’ve man­aged suc­cess­ful re­mote col­lab­o­ra­tions. In more than one case, a team has col­lab­o­rat­ed re­mote­ly for years with­out ever meet­ing in per­son. It is thrilling to watch work­ers who do meet in per­son un­der cir­cum­stances where, af­ter work­ing in­ti­mate­ly “alone, to­geth­er” over long dis­tances, it feels like a re­union of long-lost friends. But it is al­so note­wor­thy that these teams were very pro­duc­tive, even with­out ini­tial face-to-face col­lab­o­ra­tion.

For com­pa­nies fac­ing re­mote col­lab­o­ra­tions due to Covid-19, part­ners on both sides of the equa­tion will be fac­ing chal­lenges. The fol­low­ing best prac­tices ap­ply to all col­lab­o­ra­tions, but they’re more crit­i­cal than ever to­day:

  • Es­tab­lish clear vi­sion and goals: Whether in-per­son or re­mote, all re­search col­lab­o­ra­tions should have a shared vi­sion and mea­sur­able, clear goals. When teams are col­lab­o­rat­ing across re­mote lo­ca­tions with lit­tle to no in-per­son in­ter­ac­tion, this be­comes even more im­por­tant. Hav­ing a vi­sion is in­spir­ing, and it re­minds us what we’re work­ing to­ward. En­sure every­one is on the same page from day one, and build the vi­sion and goals in­to meet­ings and oth­er col­lab­o­ra­tive check­points.
  • Se­lect key col­lab­o­ra­tors thought­ful­ly: In any in­dus­try, good work re­lies on hav­ing the right team in place. Peo­ple who are in­cred­i­bly en­thu­si­as­tic and pas­sion­ate about their work can con­vey that ex­cite­ment even through a cam­era and over the phone. They should al­so be true ex­perts in com­mand of the da­ta, too — that goes for any col­lab­o­ra­tion, of course.
  • Choose the right tools — but don’t re­ly on them too much: Re­mote work is en­abled by ad­vanced tools like Slack and Zoom. But tools don’t com­mu­ni­cate — peo­ple com­mu­ni­cate. Col­lab­o­ra­tive teams need to agree on the tools sup­port­ing their work­flow, and they need to un­der­stand when, where, and what to com­mu­ni­cate. Se­lect tools that sup­port your goals, and en­sure every­one has been tech­ni­cal­ly trained and cul­tur­al­ly prepped on how to use them.
  • Prep thor­ough­ly: Tech­nol­o­gy can have short­com­ings, such as split-sec­ond lags for in­ter­na­tion­al calls, patchy au­dio, or lack of vi­su­al cues in body lan­guage. As a re­sult, or­ga­ni­za­tion and prepa­ra­tion are even more im­por­tant to cre­at­ing a good meet­ing cul­ture. Be­ing de­lib­er­ate, re­hears­ing for meet­ings, and us­ing time wise­ly will work won­ders in fa­cil­i­tat­ing smooth col­lab­o­ra­tion.
  • Be com­pas­sion­ate: Liv­ing through a cri­sis is fright­en­ing. To­day, many peo­ple are con­cerned for their health and for their loved ones. They are con­tend­ing with vast­ly shift­ed home en­vi­ron­ments, lack of child­care, and oth­er chal­lenges. Em­pa­thy is cru­cial. Build flex­i­bil­i­ty in­to col­lab­o­ra­tions to al­low sci­en­tists room to man­age dur­ing this un­prece­dent­ed time.

In­no­vat­ing for a new fu­ture in health

Biotech­nol­o­gy com­pa­nies have been de­clared es­sen­tial busi­ness­es for a rea­son — al­ready, mul­ti­ple com­pa­nies have mo­bi­lized to look for so­lu­tions to coro­n­avirus. From the im­me­di­ate cri­sis to dif­fi­cult dis­eases like Alzheimer’s and can­cer, our in­dus­try’s young com­pa­nies are the fu­ture of hu­man health. We are on track to find new ther­a­pies and cures for many dis­eases.

Col­lab­o­ra­tions are the lifeblood of our in­dus­try, and they will con­tin­ue. Our in­dus­try is in­ven­tive, and I am con­fi­dent that we will find new ways of work­ing that en­sure em­ploy­ee safe­ty and re­sult in more dis­trib­uted, more glob­al, and more fo­cused re­search. While these are un­cer­tain times, our in­dus­try-wide mis­sion to help pa­tients and save lives is as strong as ever. I en­cour­age com­pa­nies large and small to ap­proach re­mote col­lab­o­ra­tion not as an un­ten­able set­back, but rather as a new par­a­digm to con­tin­ue our cru­cial work in 2020 and be­yond.

Pearl Huang is the CEO of Cyg­nal Ther­a­peu­tics, an ear­ly-stage biotech­nol­o­gy com­pa­ny in Cam­bridge, MA.

For a look at all End­points News coro­n­avirus sto­ries, check out our spe­cial news chan­nel.

Biotech and Big Phar­ma: A blue­print for a suc­cess­ful part­ner­ship

Strategic partnerships have long been an important contributor to how drugs are discovered and developed. For decades, big pharma companies have been forming alliances with biotech innovators to increase R&D productivity, expand geographical reach and better manage late-stage commercialization costs.

Noël Brown, Managing Director and Head of Biotechnology Investment Banking, and Greg Wiederrecht, Ph.D., Managing Director in the Global Healthcare Investment Banking Group at RBC Capital Markets, are no strangers to the importance of these tie-ups. Noël has over 20 years of investment banking experience in the industry. Before moving to the banking world in 2015, Greg was the Vice President and Head of External Scientific Affairs (ESA) at Merck, where he was responsible for the scientific assessment of strategic partnership opportunities worldwide.

No­var­tis' sec­ond at­tempt to repli­cate a stun­ning can­cer re­sult falls flat

Novartis’ hopes of turning one of the most surprising trial data points of the last decade into a lung cancer drug has taken another setback.

The Swiss pharma announced Monday that its IL-1 inhibitor canakinumab did not significantly extend the lives or slow the disease progression of patients with previously untreated locally advanced or metastatic non-small cell lung cancer when compared to standard of-care alone.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,600+ biopharma pros reading Endpoints daily — and it's free.

Robert Califf (Pablo Martinez Monsivais, AP Images, File)

As buzz on Califf FDA nom heats up, in­dus­try and agency in­sid­ers of­fer a strong nod for the ‘per­fect’ choice

For once in this long, dramatic road to finding a new FDA commissioner, there’s been some continuity. Both CNN and Politico reported this weekend that Rob Califf met with President Biden to discuss the permanent commish role, following earlier news broken by the Washington Post that all signs point to Califf.

Although there may be a few Democrats who continue to grandstand about the dangers of COI (Califf has worked for Verily, sits on the board of Centessa Pharmaceuticals, and has other ties to industry research), with the pandemic ongoing and the need for some kind of continuity at FDA mounting, Califf is likely to meet the same fate as when he first won Senate confirmation in 2016, by a vote of 89-4 — Bernie Sanders and 6 others didn’t vote.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,600+ biopharma pros reading Endpoints daily — and it's free.

Stéphane Bancel, AP Images

Covid-19 roundup: Mod­er­na says vac­cine pro­duces 'strong' re­sponse in 5- to 11-year-olds; As­pen Phar­ma­care plans to up vac­cine pro­duc­tion in South Africa — re­port

After seeing a “robust” immune response in 6- to 11-year-olds dosed with its Covid-19 vaccine, Moderna says it’s headed to the FDA.

The results came from the Phase II/III KidCOVE study, which enrolled 4,753 participants between the ages of 6 and under 12 years old. The kids were given two half-doses of the Moderna vaccine (50 µg each), and showed “strong immune response” a month after the second dose.

AstraZeneca CEO Pascal Soriot (Raphael Lafargue/Abaca/Sipa USA)

A com­bo of As­traZeneca's Imfinzi and chemo wins where oth­ers have failed in piv­otal bil­iary tract test

Looking to run with the big dogs in the PD-(L)1 class, AstraZeneca’s Imfinzi has a tall hill to climb to compete in an increasingly bustling market. An aggressive combo strategy for the drug has paid off so far, and now AstraZeneca is adding another notch to its belt.

A combo of Imfinzi (durvalumab) and chemotherapy significantly extended the lives of first-line patients with advanced biliary tract cancer over chemo alone, according to topline results from the Phase III TOPAZ-1 study revealed Monday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,600+ biopharma pros reading Endpoints daily — and it's free.

Sean Ianchulev, Eyenovia CEO and CMO

Re­cent court de­ci­sion push­es FDA to re­ject and re­clas­si­fy drug-de­vice com­bo, crush­ing shares

Back in April, the FDA lost a crucial court case in which its broad discretion of regulating medical products that might satisfy the legal definitions of either “drug” and/or “medical device” was sharply curtailed.

In addition to the appeals court ruling that Genus Medical Technologies’ contrast agent barium sulfate (aka Vanilla SilQ) should not be considered a drug, as the FDA had initially ruled, but as a medical device, the agency also was forced to spell out which drugs would transition to devices as a result of the ruling.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,600+ biopharma pros reading Endpoints daily — and it's free.

Peter Greenleaf, Aurinia CEO

Af­ter pass­ing on Ac­celeron, Bris­tol My­ers eyes bolt-on ac­qui­si­tion of au­toim­mune spe­cial­ist — re­port

Bristol Myers Squibb is looking to beef up its autoimmune portfolio by scooping up Aurinia Pharmaceuticals, Bloomberg reported.

The recent overtures to Aurinia, relayed by anonymous insiders, came just as Bristol Myers turned down buyout talks with partners at Acceleron — which Merck ultimately struck a deal to acquire for $11.5 billion. Bristol Myers has reportedly decided to cash out on its minority stake, likely bagging $1.3 billion in the process, while keeping the royalty deals on two of Acceleron’s blood disorder drugs.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,600+ biopharma pros reading Endpoints daily — and it's free.

So — that pig-to-hu­man trans­plant; Po­ten­tial di­a­betes cure reach­es pa­tient; Ac­cused MIT sci­en­tist lash­es back; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

We’re incredibly excited to welcome Beth Bulik, seasoned pharma marketing reporter, to the team. You can find much of her work in our new Marketing channel — and in her weekly newsletter, Endpoints PharmaRx, which will launch in early November. Add it to your subscriptions here.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,600+ biopharma pros reading Endpoints daily — and it's free.

NYU surgeon transplants an engineered pig kidney into the outside of a brain-dead patient (Joe Carrotta/NYU Langone Health)

No, sci­en­tists are not any clos­er to pig-to-hu­man trans­plants than they were last week

Steve Holtzman was awoken by a 1 a.m. call from a doctor at Duke University asking if he could put some pigs on a plane and fly them from Ohio to North Carolina that day. A motorcyclist had gotten into a horrific crash, the doctor explained. He believed the pigs’ livers, sutured onto the patient’s skin like an external filter, might be able to tide the young man over until a donor liver became available.